[144] Avantor, Inc. SEC Filing

Rhea-AI Filing Summary

Arcutis Biotherapeutics received a Rule 144 notice for a planned sale of up to 29,131 shares of common stock, with an aggregate market value of $732,925.88. The filing lists Merrill as broker and indicates sales on NASDAQ with an approximate sale date of 11/06/2025.

The shares to be sold were acquired via restricted share vests on 05/16/2024 (17,856 shares) and 10/01/2024 (11,275 shares). The notice also shows 122,492,192 shares outstanding as context. In the past three months, the filer sold 4,504 shares for $90,262.86 on 10/02/2025. Form 144 is a notice of proposed sales by an affiliate or other holder under the rule’s volume and manner-of-sale conditions.

Insights

Securities law analyst

Routine Rule 144 sale notice; administrative and neutral.

This Form 144 lists a proposed resale of 29,131 common shares of Arcutis Biotherapeutics with an $732,925.88 market value, to be transacted on NASDAQ around 11/06/2025. It identifies acquisition via restricted stock vesting and names Merrill as broker.

Rule 144 notices are standard disclosures and do not, by themselves, change issuer fundamentals. Actual sales depend on market conditions and compliance with Rule 144 limits and methods. The excerpt notes 122,492,192 shares outstanding and a prior 3‑month sale of 4,504 shares for $90,262.86.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Flr Columbus OH 43215	29131	732925.88	122492192	11/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/16/2024	Restricted shares vest	Arcutis Biotherapeutics Inc			17856	05/16/2024	NA
Common	10/01/2024	Restricted shares vest	Arcutis Biotherapeutics Inc			11275	10/01/2024	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd Edwards 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	10/02/2025	4504	90262.86

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Arcutis Biotherapeutics disclose?

It notices a proposed resale of 29,131 common shares with an aggregate market value of $732,925.88 on NASDAQ, approximately on 11/06/2025.

How were the shares in the Form 144 acquired?

They were acquired via restricted share vesting on 05/16/2024 (17,856) and 10/01/2024 (11,275).

What is the reported number of shares outstanding?

The filing lists 122,492,192 shares outstanding for the issuer’s common stock.

Which broker is named for the proposed Rule 144 sale?

The broker listed is Merrill, with transactions planned on NASDAQ.

Were any shares sold in the past three months by the same filer?

Yes. 4,504 shares were sold on 10/02/2025 for $90,262.86.